It was never part of the plan for Boston Scientific (BSX) to have a sudden return to growth in the third quarter (or 2012, for that matter), so it's hard for me to be disappointed by the numbers that the company continues to post. The driving question for investors continues to be whether the company's seemingly endless restructuring moves and acquisitions will give it a better platform from which to grow, and/or whether the transition to new CEO Mike Mahoney will mark a turning point. Though I'm still skeptical, I have to point out that the rewards for success could be meaningful from today's level.
Please continue here:
Boston Scientific Offers More Muddle-Through